Practice parameters for sublingual immunotherapy

C. Ortolani, F. Agostinis, S. Amoroso, R. Ariano, A. Barbato, M. Bassi, G. Cadario, P. Campi, F. Cardinale, G. Ciprandi, R. D'Anneo, M. Di Gioacchino, V. Di Rienzo, A. Fiocchi, M. Galimberti, E. Galli, M. Giovannini, C. Incorvaia, S. La Grutta, C. LombardiF. Marucci, G. Marseglia, M. Minelli, A. Musarra, E. Nettis, E. Novembre, G. Pajno, G. Patriarca, F. Pezzuto, P. Piras, S. Pucci, A. Romano, C. Romano, O. Quercia, G. Scala, D. Schiavino, G. Senna, F. Sforza, M. Tosca, S. Tripodi, F. Frati

Research output: Contribution to journalArticle

Abstract

The efficacy and safety of sublingual immunotherapy (SLIT) are currently supported by clinical trials, metaanalysis and post-marketing surveys. Practice parameters for clinical use of SLIT are proposed here by a panel of Italian specialists, with reference to evidence based criteria. Indications to SLIT include allergic rhinoconjunctivitis, asthma, and i solated conjunctivitis (strength of recommendation: grade A). As to severity of the disease, SLIT is indicated in moderate/severe intermittent rhinitis, persistent rhinitis and mild to moderate asthma (grade D). SLIT may be safely prescribed also in children aged three to five years (grade B), and its use in subjects aged more than 60 years is not prevented when the indications and contraindication are ascertained (grade D). The choice of the allergen to be employed for SLIT should be made in accordance with the combination of clinical history and results of skin prick tests (grade D). Polysensitisation, i.e. the occurrence of multiple positive response does not exclude SLIT, which may be done with the clinically most important allergens (grade D). As to practical admi nistration, co-seasonal, pre co-seasonal, and continuous schedules are available, being the latter recommended for perennial allergens or for pollens with particularly prolonged pollination, such as Parietaria (grade D). For pollens with relatively short pollination, such as grasses and trees (cypress, birch, alder, hazelnut, olive) the pre coseasonal and perennial schedules are preferred (grade C). The build-up phases suggested by manufacturers can be safely used (grade A), but they can be modified according to the patient's tolerance (grade C). A duration of SLIT of 3-5 years is recommended to ensure a long-lasting clinical effect after the treatment has been terminated (grade C).

Original languageEnglish
Pages (from-to)44-46
Number of pages3
JournalMonaldi Archives for Chest Disease - Cardiac Series
Volume65
Issue number1
Publication statusPublished - Mar 2006

Fingerprint

Sublingual Immunotherapy
Allergens
Pollination
Rhinitis
Pollen
Appointments and Schedules
Asthma
Parietaria
Cupressus
Corylus
Alnus
Betula
Conjunctivitis
Olea
Poaceae
Skin Tests
Marketing
Clinical Trials
Safety

Keywords

  • Asthma
  • Conjuctivitis
  • Rhinitis
  • Sublingual immunotherapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine

Cite this

Ortolani, C., Agostinis, F., Amoroso, S., Ariano, R., Barbato, A., Bassi, M., ... Frati, F. (2006). Practice parameters for sublingual immunotherapy. Monaldi Archives for Chest Disease - Cardiac Series, 65(1), 44-46.

Practice parameters for sublingual immunotherapy. / Ortolani, C.; Agostinis, F.; Amoroso, S.; Ariano, R.; Barbato, A.; Bassi, M.; Cadario, G.; Campi, P.; Cardinale, F.; Ciprandi, G.; D'Anneo, R.; Di Gioacchino, M.; Di Rienzo, V.; Fiocchi, A.; Galimberti, M.; Galli, E.; Giovannini, M.; Incorvaia, C.; La Grutta, S.; Lombardi, C.; Marucci, F.; Marseglia, G.; Minelli, M.; Musarra, A.; Nettis, E.; Novembre, E.; Pajno, G.; Patriarca, G.; Pezzuto, F.; Piras, P.; Pucci, S.; Romano, A.; Romano, C.; Quercia, O.; Scala, G.; Schiavino, D.; Senna, G.; Sforza, F.; Tosca, M.; Tripodi, S.; Frati, F.

In: Monaldi Archives for Chest Disease - Cardiac Series, Vol. 65, No. 1, 03.2006, p. 44-46.

Research output: Contribution to journalArticle

Ortolani, C, Agostinis, F, Amoroso, S, Ariano, R, Barbato, A, Bassi, M, Cadario, G, Campi, P, Cardinale, F, Ciprandi, G, D'Anneo, R, Di Gioacchino, M, Di Rienzo, V, Fiocchi, A, Galimberti, M, Galli, E, Giovannini, M, Incorvaia, C, La Grutta, S, Lombardi, C, Marucci, F, Marseglia, G, Minelli, M, Musarra, A, Nettis, E, Novembre, E, Pajno, G, Patriarca, G, Pezzuto, F, Piras, P, Pucci, S, Romano, A, Romano, C, Quercia, O, Scala, G, Schiavino, D, Senna, G, Sforza, F, Tosca, M, Tripodi, S & Frati, F 2006, 'Practice parameters for sublingual immunotherapy', Monaldi Archives for Chest Disease - Cardiac Series, vol. 65, no. 1, pp. 44-46.
Ortolani C, Agostinis F, Amoroso S, Ariano R, Barbato A, Bassi M et al. Practice parameters for sublingual immunotherapy. Monaldi Archives for Chest Disease - Cardiac Series. 2006 Mar;65(1):44-46.
Ortolani, C. ; Agostinis, F. ; Amoroso, S. ; Ariano, R. ; Barbato, A. ; Bassi, M. ; Cadario, G. ; Campi, P. ; Cardinale, F. ; Ciprandi, G. ; D'Anneo, R. ; Di Gioacchino, M. ; Di Rienzo, V. ; Fiocchi, A. ; Galimberti, M. ; Galli, E. ; Giovannini, M. ; Incorvaia, C. ; La Grutta, S. ; Lombardi, C. ; Marucci, F. ; Marseglia, G. ; Minelli, M. ; Musarra, A. ; Nettis, E. ; Novembre, E. ; Pajno, G. ; Patriarca, G. ; Pezzuto, F. ; Piras, P. ; Pucci, S. ; Romano, A. ; Romano, C. ; Quercia, O. ; Scala, G. ; Schiavino, D. ; Senna, G. ; Sforza, F. ; Tosca, M. ; Tripodi, S. ; Frati, F. / Practice parameters for sublingual immunotherapy. In: Monaldi Archives for Chest Disease - Cardiac Series. 2006 ; Vol. 65, No. 1. pp. 44-46.
@article{a0c0ab9b4d8a4bba96e9c2aa7310ad69,
title = "Practice parameters for sublingual immunotherapy",
abstract = "The efficacy and safety of sublingual immunotherapy (SLIT) are currently supported by clinical trials, metaanalysis and post-marketing surveys. Practice parameters for clinical use of SLIT are proposed here by a panel of Italian specialists, with reference to evidence based criteria. Indications to SLIT include allergic rhinoconjunctivitis, asthma, and i solated conjunctivitis (strength of recommendation: grade A). As to severity of the disease, SLIT is indicated in moderate/severe intermittent rhinitis, persistent rhinitis and mild to moderate asthma (grade D). SLIT may be safely prescribed also in children aged three to five years (grade B), and its use in subjects aged more than 60 years is not prevented when the indications and contraindication are ascertained (grade D). The choice of the allergen to be employed for SLIT should be made in accordance with the combination of clinical history and results of skin prick tests (grade D). Polysensitisation, i.e. the occurrence of multiple positive response does not exclude SLIT, which may be done with the clinically most important allergens (grade D). As to practical admi nistration, co-seasonal, pre co-seasonal, and continuous schedules are available, being the latter recommended for perennial allergens or for pollens with particularly prolonged pollination, such as Parietaria (grade D). For pollens with relatively short pollination, such as grasses and trees (cypress, birch, alder, hazelnut, olive) the pre coseasonal and perennial schedules are preferred (grade C). The build-up phases suggested by manufacturers can be safely used (grade A), but they can be modified according to the patient's tolerance (grade C). A duration of SLIT of 3-5 years is recommended to ensure a long-lasting clinical effect after the treatment has been terminated (grade C).",
keywords = "Asthma, Conjuctivitis, Rhinitis, Sublingual immunotherapy",
author = "C. Ortolani and F. Agostinis and S. Amoroso and R. Ariano and A. Barbato and M. Bassi and G. Cadario and P. Campi and F. Cardinale and G. Ciprandi and R. D'Anneo and {Di Gioacchino}, M. and {Di Rienzo}, V. and A. Fiocchi and M. Galimberti and E. Galli and M. Giovannini and C. Incorvaia and {La Grutta}, S. and C. Lombardi and F. Marucci and G. Marseglia and M. Minelli and A. Musarra and E. Nettis and E. Novembre and G. Pajno and G. Patriarca and F. Pezzuto and P. Piras and S. Pucci and A. Romano and C. Romano and O. Quercia and G. Scala and D. Schiavino and G. Senna and F. Sforza and M. Tosca and S. Tripodi and F. Frati",
year = "2006",
month = "3",
language = "English",
volume = "65",
pages = "44--46",
journal = "Monaldi Archives for Chest Disease",
issn = "1122-0643",
publisher = "Fondazione Salvatore Maugeri",
number = "1",

}

TY - JOUR

T1 - Practice parameters for sublingual immunotherapy

AU - Ortolani, C.

AU - Agostinis, F.

AU - Amoroso, S.

AU - Ariano, R.

AU - Barbato, A.

AU - Bassi, M.

AU - Cadario, G.

AU - Campi, P.

AU - Cardinale, F.

AU - Ciprandi, G.

AU - D'Anneo, R.

AU - Di Gioacchino, M.

AU - Di Rienzo, V.

AU - Fiocchi, A.

AU - Galimberti, M.

AU - Galli, E.

AU - Giovannini, M.

AU - Incorvaia, C.

AU - La Grutta, S.

AU - Lombardi, C.

AU - Marucci, F.

AU - Marseglia, G.

AU - Minelli, M.

AU - Musarra, A.

AU - Nettis, E.

AU - Novembre, E.

AU - Pajno, G.

AU - Patriarca, G.

AU - Pezzuto, F.

AU - Piras, P.

AU - Pucci, S.

AU - Romano, A.

AU - Romano, C.

AU - Quercia, O.

AU - Scala, G.

AU - Schiavino, D.

AU - Senna, G.

AU - Sforza, F.

AU - Tosca, M.

AU - Tripodi, S.

AU - Frati, F.

PY - 2006/3

Y1 - 2006/3

N2 - The efficacy and safety of sublingual immunotherapy (SLIT) are currently supported by clinical trials, metaanalysis and post-marketing surveys. Practice parameters for clinical use of SLIT are proposed here by a panel of Italian specialists, with reference to evidence based criteria. Indications to SLIT include allergic rhinoconjunctivitis, asthma, and i solated conjunctivitis (strength of recommendation: grade A). As to severity of the disease, SLIT is indicated in moderate/severe intermittent rhinitis, persistent rhinitis and mild to moderate asthma (grade D). SLIT may be safely prescribed also in children aged three to five years (grade B), and its use in subjects aged more than 60 years is not prevented when the indications and contraindication are ascertained (grade D). The choice of the allergen to be employed for SLIT should be made in accordance with the combination of clinical history and results of skin prick tests (grade D). Polysensitisation, i.e. the occurrence of multiple positive response does not exclude SLIT, which may be done with the clinically most important allergens (grade D). As to practical admi nistration, co-seasonal, pre co-seasonal, and continuous schedules are available, being the latter recommended for perennial allergens or for pollens with particularly prolonged pollination, such as Parietaria (grade D). For pollens with relatively short pollination, such as grasses and trees (cypress, birch, alder, hazelnut, olive) the pre coseasonal and perennial schedules are preferred (grade C). The build-up phases suggested by manufacturers can be safely used (grade A), but they can be modified according to the patient's tolerance (grade C). A duration of SLIT of 3-5 years is recommended to ensure a long-lasting clinical effect after the treatment has been terminated (grade C).

AB - The efficacy and safety of sublingual immunotherapy (SLIT) are currently supported by clinical trials, metaanalysis and post-marketing surveys. Practice parameters for clinical use of SLIT are proposed here by a panel of Italian specialists, with reference to evidence based criteria. Indications to SLIT include allergic rhinoconjunctivitis, asthma, and i solated conjunctivitis (strength of recommendation: grade A). As to severity of the disease, SLIT is indicated in moderate/severe intermittent rhinitis, persistent rhinitis and mild to moderate asthma (grade D). SLIT may be safely prescribed also in children aged three to five years (grade B), and its use in subjects aged more than 60 years is not prevented when the indications and contraindication are ascertained (grade D). The choice of the allergen to be employed for SLIT should be made in accordance with the combination of clinical history and results of skin prick tests (grade D). Polysensitisation, i.e. the occurrence of multiple positive response does not exclude SLIT, which may be done with the clinically most important allergens (grade D). As to practical admi nistration, co-seasonal, pre co-seasonal, and continuous schedules are available, being the latter recommended for perennial allergens or for pollens with particularly prolonged pollination, such as Parietaria (grade D). For pollens with relatively short pollination, such as grasses and trees (cypress, birch, alder, hazelnut, olive) the pre coseasonal and perennial schedules are preferred (grade C). The build-up phases suggested by manufacturers can be safely used (grade A), but they can be modified according to the patient's tolerance (grade C). A duration of SLIT of 3-5 years is recommended to ensure a long-lasting clinical effect after the treatment has been terminated (grade C).

KW - Asthma

KW - Conjuctivitis

KW - Rhinitis

KW - Sublingual immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=33646385350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646385350&partnerID=8YFLogxK

M3 - Article

C2 - 16700194

AN - SCOPUS:33646385350

VL - 65

SP - 44

EP - 46

JO - Monaldi Archives for Chest Disease

JF - Monaldi Archives for Chest Disease

SN - 1122-0643

IS - 1

ER -